Biomedical Firm MaxHealth Raises ￥100M in Pre-A Round

According to lieyunwang.com, Chengdu MaxHealth biotechnology Co., Ltd. ("MaxHealth"), a biomedical company focused on the R&D of vaccines has announced the completion of its Pre-A financing round of nearly 100 million yuan, from Korea Investment Partners. Proceeds from this round will mainly be used to support the clinical trials of the herpes zoster zostavax vaccine and the new rotavirus vaccine.

MaxHealth completed its angel round financing of tens of millions yuan in December 2017.

Founded in April 2016, MaxHealth has the innovative adjuvant platform and recombinant protein platform. There are several vaccine projects under clinical application, including the therapeutic vaccines for major infectious diseases, allergic diseases, and cancers.

Chen Dexiang, founder of MaxHealth, has worked in the US vaccine industry for 25 years, first at Wyeth (now Pfizer) and PowderJect (now GSK), and most recently at PATH, a global health organization.

At present, MaxHealth holds more than 10 international cutting-edge technologies and more than 20 invention patents, among which the company's self-developed herpes zoster zostavax vaccine and rotavirus vaccine have respectively completed the development and evaluation of the pre-clinical process, and the declaration of IND is expected to be completed by the end of this year.

Fu hao, vice President of Korea Investment Partners, said, "The vaccine industry in China is quite different from that in other countries in terms of technology and safety incidents. It's good to see that we've recently seen great teams who are innovating and trying to change that. It is a great honor to work with MaxHealth to accelerate the development of the vaccine industry in China."

KIP is a leading venture capital & private equity firm that has over 30 years of experience in providing venture capital to bold and innovative entrepreneurs who want to change the world. 

KIP manages over 20 venture and private equity funds with US$1.8 billion in total assets under management. The company operates globally from its Seoul headquarters office with other locations in Shanghai, Beijing, and Sunnyvale.